Fig. 6From: Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancerThree-dimensional (3D) structure related to the interaction between FGFR3 protein and approved drugs. A Pemigatinib. B Infigratinib. C Nintedanib. D Ponatinib. Yellow color indicates molecular bonds (hydrogen and hydrophobic), blue color indicates approved drugs and green color was used to improve differentiate of molecular bondsBack to article page